# language_name_wals:	English
# language_name_glotto:	English
# ISO_6393:	eng
# year_composed:	NA
# year_published:	NA
# mode:	written
# genre_broad:	technical
# genre_narrow:	NA
# writing_system:	Latn
# special_characters:	NA
# short_description:	EMEA
# source:	https://object.pouta.csc.fi/OPUS-EMEA/v3/raw/en.zip
# copyright_short:	http://opus.nlpl.eu/EMEA.php
# copyright_long:	http://opus.nlpl.eu/EMEA.php J. Tiedemann, 2012, Parallel Data, Tools and Interfaces in OPUS. In Proceedings of the 8th International Conference on Language Resources and Evaluation (LREC 2012)
# sample_type:	whole
# comments:	NA

ANNEX
CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT TO BE IMPLEMENTED BY THE MEMBER STATES
1 CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT TO BE IMPLEMENTED BY THE MEMBER STATES
The Marketing Authorisation Holder (MAH) shall ensure that, at launch, all healthcare professionals who are experienced to prescribe/ use Thymanax are provided with educational materials containing the following:
As described in the RMP, additional risk minimisation activity including educational material will be provided to prescribers.
Objectives of agomelatine Educational Plan:
The prescriber educational material about Valdoxan / Thymanax will be focused on:
- The potential risks of agomelatine
- Transaminases Elevations
- Interactions with potent CYP 1A2 inhibitors (e. g. fluvoxamine, ciprofloxacin).
- Guidance for hepatic function screening (Need to perform liver function tests in all patients: at initiation
of treatment, and then periodically after around six weeks (end of acute phase), twelve weeks and twenty four weeks (end of maintenance phase) and thereafter when clinically indicated;
- Guidance in case of clinical symptoms or liver function tests abnormality;
- Caution to be exercised when therapy is administered to patients who consume substantial quantities of
alcohol or who are treated with medicinal products associated with risk of hepatic injury;
- Contra-indication in patients with hepatic impairment (i. e. cirrhosis or active liver disease);
- Contra-indication in patients receiving concomitantly potent CYP1A2 inhibitors.
2